Display options
Share it on

Hemodial Int. 2001 Jan;5(1):86-91. doi: 10.1111/hdi.2001.5.1.86.

Pathophysiology and Treatment of Hyperhomocysteinemia in End-Stage Renal Disease Patients.

Hemodialysis international. International Symposium on Home Hemodialysis

G Sunder-Plassmann, Walter H Hörl

Affiliations

  1. Division of Nephrology, Department of Medicine, University of Vienna, Vienna, Austria.

PMID: 28452434 DOI: 10.1111/hdi.2001.5.1.86

Abstract

The pathophysiology of hyperhomocysteinemia in end-stage renal disease (ESRD) patients includes impaired remethylation of homocysteine (Hcy) to methionine, inhibition of extrarenal Hcy metabolism by uremic solutes, a block in decarboxylation of cysteinesulfinic acid, impaired [adenosylmethionine]/[adenosylhomocysteine] ratio, and a probable impairment of renal Hcy metabolism and excretion. Treatment of hyperhomocysteinemia in ESRD patients includes administration of folic acid (1 - 15 mg per day). No additional effects have been observed with higher folic acid doses, folinic acid, or 5-methyltetrahydrofolate. Oral supplementation with vitamin B

Keywords: Homocysteine; folic acid; renal failure

Publication Types